Top Markets
#1 Black Phoenix Black Phoenix +828.60%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.27%
#3 Beam Beam +25.92%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +23.39%
#5 SAFEcoin SAFEcoin +20.79%
#6 Magma Finance Magma Finance +19.47%
#7 pipedog pipedog +19.13%
#8 Bless Bless +16.57%
#9 PondCoin PondCoin +16.30%
#10 THORChain THORChain +15.72%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Clasificación en acciones #6078
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Precio por acción
$32.48
Última sincronización: 2024-03-25
Capitalización bursátil
$2.24B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio CymaBay Therapeutics, Inc. (CBAY)

Categoría

Healthcare
Historial del precio de la acción de CymaBay Therapeutics, Inc. (CBAY)
Precio más alto de cierre: $32.39 el 2024-03-01

Precio más bajo de cierre: $9.00 el 2014-02-01
Historial del precio de la acción de CymaBay Therapeutics, Inc. desde 2014 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2024 47.52%
2023 374.76%
2022 35.77%
2021 -49.78%
2020 272.39%
2019 -77.25%
2018 -6.63%
2017 374.80%
2016 15.85%
2015 -81.43%
2014 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.46 40.96%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 49.73%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.63 -12.65%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $140.98 461.67%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.19%
CH